Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
Public ClinicalTrials.gov record NCT03227029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age
Study identification
- NCT ID
- NCT03227029
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- RSV 276 Biological
- RSV ΔNS2/Δ1313/I1314L Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Months to 24 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2017
- Primary completion
- Dec 18, 2019
- Completion
- Sep 30, 2020
- Last update posted
- Apr 21, 2022
2017 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program | La Jolla | California | 92093-0672 | — |
| Usc La Nichd Crs | Los Angeles | California | 90089 | — |
| David Geffen School of Medicine at UCLA NICHD CRS | Los Angeles | California | 90095-1752 | — |
| Univ. of Colorado Denver NICHD CRS | Aurora | Colorado | 80045 | — |
| Rush Univ. Cook County Hosp. Chicago NICHD CRS | Chicago | Illinois | 60612 | — |
| Lurie Children's Hospital of Chicago (LCH) CRS | Chicago | Illinois | 60614-3393 | — |
| Johns Hopkins University Center for Immunization Research | Baltimore | Maryland | 21205 | — |
| Boston Medical Center Ped. HIV Program NICHD CRS | Boston | Massachusetts | 02118 | — |
| SUNY Stony Brook NICHD CRS | Stony Brook | New York | 11794 | — |
| Jacobi Med. Ctr. Bronx NICHD CRS | The Bronx | New York | 10461 | — |
| St. Jude Children's Research Hospital CRS | Memphis | Tennessee | 38105-3678 | — |
| Texas Children's Hospital CRS | Houston | Texas | 77030-2399 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03227029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2022 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03227029 live on ClinicalTrials.gov.